A PHASE I TRIAL OF RADIOIMMUNOTHERAPY (Y-90 CT8466), GEMCITABINE AND HEPATIC

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 目的：测定结直肠癌患者肝切除或最大限度手术切除肝转移瘤(至3 cm)后同时肝动脉灌注(HAI)氟代脱氧吡胺(FUDR)和静脉注射吉西他滨联合静脉注射Yttrium-90嵌合T84.66的最大耐受量(MTD)和相关毒性；研究肝转移瘤切除和/或消融后这种辅助治疗的可行性和毒性；评价Yttrium-90和In111嵌合T84.66静脉注射的生物分布、清除和代谢；通过连续核成像估计全身、正常器官和肿瘤的辐射剂量；将治疗前后的蛋白质组学特征与毒性和抗肿瘤作用相关联。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives are to determine the maximum tolerated dose (MTD) and associated toxicities of concurrent hepatic arterial infusion (HAI) fluorodeoxypyrimide (FUdR) and intravenous gemcitabine combined with intravenous Yttrium-90 chimeric T84.66 in colorectal cancer patients after hepatic resection or maximum surgical debulking (to <3cm) of liver metastases; to study the feasibility and toxicities of such adjuvant therapy following resection and/or ablation of liver metastases; to evaluate the biodistribution, clearance and metabolism of Yttrium-90 and Indium-111 chimeric T84.66 administered intravenously; to estimate radiation doses to whole body, normal organs and tumor through serial nuclear imaging; to correlate proteomic profiles pre and post-therapy with toxicities and anti-tumor effects.